Restricted to use in severe disease (defined by a total Psoriasis Area Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of >10) under the discount agreed in the patient access scheme. Treatment should be stopped if the psoriasis has not responded adequately at 16 weeks (adequate response defined as a 75% reduction in the PASI score (PASI 75) from when treatment started, or a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from start of treatment). This guidance replaces NICE TA368, which did not recommend the use of apremilast for this indication.